Patents by Inventor John Cameron Bell
John Cameron Bell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240026380Abstract: The present disclosure provides a miRNA hairpin that, when processed by a virus-infected cell, increases the therapeutic effectiveness of the virus. The present disclosure also provides a virus encoding such a miRNA hairpin. The present disclosure also provides pre-miRNAs that, when processed by a virus-infected cell, increase extracellular vesicle secretion of the encoded miRNA hairpin by the virus-infected cell.Type: ApplicationFiled: June 28, 2023Publication date: January 25, 2024Inventors: Carolina Solange ILKOW, John Cameron BELL, Victoria Ann MAHER, Briana Livia Rollande SAMSON
-
Patent number: 11739350Abstract: The present disclosure provides a miRNA hairpin that, when processed by a virus-infected cell, increases the therapeutic effectiveness of the virus. The present disclosure also provides a virus encoding such a miRNA hairpin. The present disclosure also provides pre-miRNAs that, when processed by a virus-infected cell, increase extracellular vesicle secretion of the encoded miRNA hairpin by the virus-infected cell.Type: GrantFiled: April 10, 2019Date of Patent: August 29, 2023Assignee: OTTAWA HOSPITAL RESEARCH INSTITUTEInventors: Carolina Solange Ilkow, John Cameron Bell, Victoria Ann Maher, Briana Livia Rollande Samson
-
Publication number: 20230203532Abstract: Herein is provided a recombinant tumor-selective viral particle comprising a nucleic acid encoding a recombinant polypeptide for directing an extracellular vesicle (EV) to at least one target cell, said recombinant polypeptide comprising: at least one targeting moiety for directing said EV to said at least one target molecule expressed by said at least one target cell; at least one EV-anchoring polypeptide; and at least one intravesicular polypeptide. The viral particle may be from an oncolytic viruses. Recombinant polypeptides for programming EVs to target particular molecules are also provided. Also described are therapeutic EVs for delivering payload polypeptides (and/or cargo molecules) to target cells, e.g., in vaccine or cell-free “CAR-T”-like applications, along with EVs for recruiting immune cells to target cells in EV-mediated BiTE -like applications. Oncolytic viruses may also be engineered to infect tumor cells and shed programmed EVs, yielding additional therapeutic effects.Type: ApplicationFiled: November 27, 2020Publication date: June 29, 2023Inventors: Carlolina Solange ILKOW, John Cameron BELL, Jack Timothy WHELAN, Mathieu François Joseph CRUPI, Jessie Nhan DUONG, Brian Dennis LICHTY, Matthew John ATHERTON, Fuan WANG, Yoanna Poutou PAUMIER, Stephen Donald BOULTON, Mohammadtaha MOHAMMADIAZAD, Ragunath SINGARAVELU
-
Patent number: 11590184Abstract: Disclosed herein is an oncolytic recombinant Maraba virus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof. A method for treating a cancer in a patient using the oncolytic recombinant Maraba virus is also disclosed. The present disclosure also provides a tumour cell infected with an oncolytic rhabdovirus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof, for use as an infected cell vaccine (ICV) for the treatment of a cancer. A method for treating a cancer in a patient using the infected cell vaccine is also disclosed.Type: GrantFiled: August 9, 2017Date of Patent: February 28, 2023Assignee: TURNSTONE LIMITED PARTNERSHIPInventors: Almohanad Alkayyal, Rebecca Auer, John Cameron Bell
-
Publication number: 20210346441Abstract: There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties.Type: ApplicationFiled: July 21, 2021Publication date: November 11, 2021Inventors: David Conrad, Cory Batenchuk, Fabrice Leboeuf, John Cameron Bell
-
Patent number: 11110138Abstract: There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties.Type: GrantFiled: December 20, 2013Date of Patent: September 7, 2021Assignee: CELVERUM INC.Inventors: David Conrad, Cory Batenchuk, Fabrice Leboeuf, John Cameron Bell
-
Publication number: 20210128706Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: ApplicationFiled: September 9, 2020Publication date: May 6, 2021Applicant: TURNSTONE LIMITED PARTNERSHIPInventors: David F. STOJDL, John Cameron BELL, Brian LICHTY, Jonathan POL
-
Publication number: 20210032662Abstract: The present disclosure provides a miRNA hairpin that, when processed by a virus-infected cell, increases the therapeutic effectiveness of the virus. The present disclosure also provides a virus encoding such a miRNA hairpin. The present disclosure also provides pre-miRNAs that, when processed by a virus-infected cell, increase extracellular vesicle secretion of the encoded miRNA hairpin by the virus-infected cell.Type: ApplicationFiled: April 10, 2019Publication date: February 4, 2021Inventors: Carolina Solange ILKOW, John Cameron BELL, Victoria Ann MAHER, Briana Livia Rollande SAMSON
-
Patent number: 10660947Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: GrantFiled: January 16, 2019Date of Patent: May 26, 2020Assignee: TURNSTONE LIMITED PARTNERSHIPInventors: David F. Stojdl, John Cameron Bell, Brian Lichty
-
Patent number: 10646557Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: GrantFiled: January 16, 2019Date of Patent: May 12, 2020Assignee: TURNSTONE LIMITED PARTNERSHIPInventors: David F. Stojdl, John Cameron Bell, Brian Lichty
-
Patent number: 10604741Abstract: Described herein is a method of enhancing virus replication in permissive cells that express a receptor to FGF2 protein. The method includes administering FGF2 protein or a functional variant thereof and the virus to the permissive cells. An oncolytic virus having a genome that includes an open reading frame that encodes FGF2 protein or a functional variant thereof is also described.Type: GrantFiled: March 13, 2018Date of Patent: March 31, 2020Assignee: TURNSTONE LIMITED PARTNERSHIPInventors: Carolina Solange Ilkow, Fabrice Le Boeuf, John Cameron Bell, Jean-Simon Diallo, Rozanne Arulanandam
-
Publication number: 20190255160Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: ApplicationFiled: January 16, 2019Publication date: August 22, 2019Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty, Jonathan Pol
-
Publication number: 20190240301Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: ApplicationFiled: January 16, 2019Publication date: August 8, 2019Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty, Jonathan Pol
-
Patent number: 10363293Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: GrantFiled: February 20, 2014Date of Patent: July 30, 2019Assignee: Turnstone Limited PartnershipInventors: David F. Stojdl, John Cameron Bell, Brian Lichty, Jonathan Pol
-
Publication number: 20190216868Abstract: Disclosed herein is an oncolytic recombinant Maraba virus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof. A method for treating a cancer in a patient using the oncolytic recombinant Maraba virus is also disclosed. The present disclosure also provides a tumour cell infected with an oncolytic rhabdovirus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof, for use as an infected cell vaccine (ICV) for the treatment of a cancer. A method for treating a cancer in a patient using the infected cell vaccine is also disclosed.Type: ApplicationFiled: August 9, 2017Publication date: July 18, 2019Inventors: Almohanad Alkayyal, Rebecca Auer, John Cameron Bell
-
Patent number: 10066214Abstract: Described herein is a method of enhancing virus replication in permissive cells that express a receptor to FGF2 protein. The method includes administering FGF2 protein or a functional variant thereof and the virus to the permissive cells. An oncolytic virus having a genome that includes an open reading frame that encodes FGF2 protein or a functional variant thereof is also described.Type: GrantFiled: June 16, 2014Date of Patent: September 4, 2018Assignee: Turnstone Limited PartnershipInventors: Carolina Solange Ilkow, Fabrice Le Boeuf, John Cameron Bell, Jean-Simon Diallo, Rozanne Arulanandam
-
Publication number: 20180237753Abstract: Described herein is a method of enhancing virus replication in permissive cells that express a receptor to FGF2 protein. The method includes administering FGF2 protein or a functional variant thereof and the virus to the permissive cells. An oncolytic virus having a genome that includes an open reading frame that encodes FGF2 protein or a functional variant thereof is also described.Type: ApplicationFiled: March 13, 2018Publication date: August 23, 2018Inventors: Carolina Solange ILKOW, Fabrice LE BOEUF, John Cameron BELL, Jean-Simon DIALLO, Rozanne ARULANANDAM
-
Patent number: 9623096Abstract: An immunogenic formulation for a patient, the formulation includes virus-modulated hematopoietic cancer cells, where the modulated hematopoietic cancer cells are generated from viable hematopoietic cancer cells obtained from the patient, either isolated or in a mixed hematopoietic population of healthy and cancer cells, and where the viable hematopoietic cancer cells are infected ex vivo with a virus that modulates the expression of a plurality of endogenous immune regulatory molecules to increase the immunogenicity of the hematopoietic cancer cells.Type: GrantFiled: November 8, 2012Date of Patent: April 18, 2017Assignee: Celverum Inc.Inventors: David Conrad, John Cameron Bell, Harry Atkins
-
Publication number: 20160130563Abstract: Described herein is a method of enhancing virus replication in permissive cells that express a receptor to FGF2 protein. The method includes administering FGF2 protein or a functional variant thereof and the virus to the permissive cells. An oncolytic virus having a genome that includes an open reading frame that encodes FGF2 protein or a functional variant thereof is also described.Type: ApplicationFiled: June 16, 2014Publication date: May 12, 2016Inventors: Carolina Solange ILKOW, Fabrice LE BOEUF, John Cameron BELL, Jean-Simon DIALLO, Rozanne ARULANANDAM
-
Publication number: 20160106820Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: ApplicationFiled: February 20, 2014Publication date: April 21, 2016Applicants: CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC., OTTAWA HOSPITAL RESEARCH INSTITUTE, MCMASTER UNIVERSITYInventors: David F. STOJDL, John Cameron BELL, Brian LICHTY, Jonathan POL